Chief
James L. Gulley, M.D., Ph.D.
Deputy Chief
William Douglas Figg, Sr., Pharm.D.

Center for Cancer Research
National Cancer Institute

Building 10, Room 13N240
Bethesda, MD 20892
301-480.8870

James L. Gulley, M.D., Ph.D.
Chief, Genitourinary Malignancies Branch

The Genitourinary Malignancies Branch focuses on investigating the biology of genitourinary cancers, developing new strategies for treating those cancers, and evaluating these new therapeutic approaches through science-driven clinical research. These clinical trials investigate novel approaches in immunotherapy, hormonal therapy, chemotherapy combinations, and small-molecule targeted therapy. This website provides all interested parties—referring physicians, cancer patients or family members interested in participating in a clinical trial, or researchers looking for collaborative opportunities—with the information they need to get started.


Support Services


As part of our comprehensive care we provide clinical trials for a wide range of different malignancies with a focus on prostate cancer and bladder cancer. Our patients are provided guidance and assistance with appointments, travel, counseling and social support throughout the process and follow up. We also believe strongly in collaborating with your primary care physician (with your permission) to form your "expert care team." Before your first visit, we may ask you to provide medical records, CDs with MRIs, CTs, or PET scans, and a list of medications.

  • Consultations are at no cost to the patient.

  • After a patient is accepted on a study, treatments, tests and other services at the NIH Clinical Center are also no cost.

  • NIH does not cover expenses for medical services at other facilities.

  • We are located on the NIH campus in Bethesda, Maryland, approximately 8 miles north of Washington, D.C.

  • The Genitourinary Malignancies Branch Clinic is on the 12th floor of the Magnuson Clinical Center (Building 10).

  • Visitor information is available at NIH Clinical Center - Access and Directions (View Map).


Contact Information



Prostate Cancer/Immunotherapy



Bladder Cancer


  • Nurse Practitioners/Registered Nurses
    • Marilise Berniger
    • Deneise Francis
  • Patient Care Coordinator
    • Moniquea Smith
  • Staff
    • Andrea Apolo, MD
    • Yang-min (Max) Ning, MD
    • Howard Parnes, MD
    • Rosa Nadal Rios, MD, PhD
  • Other Staff
    • Lisa Cordes, PharmD
    • Elaine De Benedetto, MSN
    • Corrine Keen, RN


Our Science


  • James L. Gulley, M.D., Ph.D. is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the NCI. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, Dr. Gulley played a central role in the clinical development of a prostate cancer vaccine, created in the NCI, and serves as the principal investigator on an international Phase III randomized clinical trial of this vaccine. He is also the coordinating principal investigator of an international trial of an anti-PDL1 antibody.

    Dr. Gulley is also Director of the Medical Oncology Service and the NCI Immunotherapy Fellowship Program.

  • William Douglas Figg Sr., Pharm.D. is an expert on utilizing pharmacological principles in anticancer drug and biomarker development. He has integrated pharmacogenetics/pharmacogenomics research in these drug development efforts to evaluate the impact of genetic variants on drug metabolism, response and toxicity. His research focuses on the development of novel therapies, using prostate cancer as the target disease and angiogenesis as the target pathway.  Dr. Figg is Deputy Branch Chief.

  • Andrea B. Apolo, M.D. is dedicated to improving the treatment and survival of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular, she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Other research focuses include improving tumor detection by using new imaging modalities in bladder and prostate cancer and identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease.

  • William L. Dahut, M.D. is working to improve therapy for men with advanced prostate cancer. He has pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy and other more traditional modalities. His recent studies combining immunotherapy with more standard treatment have been active and demonstrated the ability to maintain a robust immunologic response.

    Dr. Dahut is also the Scientific Director for Clinical Research at CCR.

  • Ravi A. Madan, M.D. is the Clinical Director of the Genitourinary Malignancies Branch. His research focuses on immune-stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.

  • Marijo Bilusic, M.D., Ph.D. is Associate Program Director of the NIH Hematology and Oncology Fellowship Program. His current research interests focus on tumor immunology and development of treatment options for prostate cancer and other genitourinary tumors using novel targeted agents, therapeutic cancer vaccines, antibodies, or immune modulators.

About

James L. Gulley, M.D., Ph.D.
Chief, Genitourinary Malignancies Branch

The Genitourinary Malignancies Branch focuses on investigating the biology of genitourinary cancers, developing new strategies for treating those cancers, and evaluating these new therapeutic approaches through science-driven clinical research. These clinical trials investigate novel approaches in immunotherapy, hormonal therapy, chemotherapy combinations, and small-molecule targeted therapy. This website provides all interested parties—referring physicians, cancer patients or family members interested in participating in a clinical trial, or researchers looking for collaborative opportunities—with the information they need to get started.

Referrals


Contact Information


For Patients


Support Services


As part of our comprehensive care we provide clinical trials for a wide range of different malignancies with a focus on prostate cancer and bladder cancer. Our patients are provided guidance and assistance with appointments, travel, counseling and social support throughout the process and follow up. We also believe strongly in collaborating with your primary care physician (with your permission) to form your "expert care team." Before your first visit, we may ask you to provide medical records, CDs with MRIs, CTs, or PET scans, and a list of medications.

  • Consultations are at no cost to the patient.

  • After a patient is accepted on a study, treatments, tests and other services at the NIH Clinical Center are also no cost.

  • NIH does not cover expenses for medical services at other facilities.

  • We are located on the NIH campus in Bethesda, Maryland, approximately 8 miles north of Washington, D.C.

  • The Genitourinary Malignancies Branch Clinic is on the 12th floor of the Magnuson Clinical Center (Building 10).

  • Visitor information is available at NIH Clinical Center - Access and Directions (View Map).

Teams


Prostate Cancer/Immunotherapy



Bladder Cancer


  • Nurse Practitioners/Registered Nurses
    • Marilise Berniger
    • Deneise Francis
  • Patient Care Coordinator
    • Moniquea Smith
  • Staff
    • Andrea Apolo, MD
    • Yang-min (Max) Ning, MD
    • Howard Parnes, MD
    • Rosa Nadal Rios, MD, PhD
  • Other Staff
    • Lisa Cordes, PharmD
    • Elaine De Benedetto, MSN
    • Corrine Keen, RN

For Trainees

Our Science


Our Science


  • James L. Gulley, M.D., Ph.D. is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the NCI. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, Dr. Gulley played a central role in the clinical development of a prostate cancer vaccine, created in the NCI, and serves as the principal investigator on an international Phase III randomized clinical trial of this vaccine. He is also the coordinating principal investigator of an international trial of an anti-PDL1 antibody.

    Dr. Gulley is also Director of the Medical Oncology Service and the NCI Immunotherapy Fellowship Program.

  • William Douglas Figg Sr., Pharm.D. is an expert on utilizing pharmacological principles in anticancer drug and biomarker development. He has integrated pharmacogenetics/pharmacogenomics research in these drug development efforts to evaluate the impact of genetic variants on drug metabolism, response and toxicity. His research focuses on the development of novel therapies, using prostate cancer as the target disease and angiogenesis as the target pathway.  Dr. Figg is Deputy Branch Chief.

  • Andrea B. Apolo, M.D. is dedicated to improving the treatment and survival of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular, she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Other research focuses include improving tumor detection by using new imaging modalities in bladder and prostate cancer and identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease.

  • William L. Dahut, M.D. is working to improve therapy for men with advanced prostate cancer. He has pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy and other more traditional modalities. His recent studies combining immunotherapy with more standard treatment have been active and demonstrated the ability to maintain a robust immunologic response.

    Dr. Dahut is also the Scientific Director for Clinical Research at CCR.

  • Ravi A. Madan, M.D. is the Clinical Director of the Genitourinary Malignancies Branch. His research focuses on immune-stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.

  • Marijo Bilusic, M.D., Ph.D. is Associate Program Director of the NIH Hematology and Oncology Fellowship Program. His current research interests focus on tumor immunology and development of treatment options for prostate cancer and other genitourinary tumors using novel targeted agents, therapeutic cancer vaccines, antibodies, or immune modulators.